{"id":"intravenous-amiodarone-2","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Hypotension"},{"rate":"5-10","effect":"Bradycardia"},{"rate":"5-10","effect":"Phlebitis at injection site"},{"rate":"5-10","effect":"Nausea"},{"rate":"1-5","effect":"Pulmonary toxicity (chronic use)"},{"rate":"5-10","effect":"Thyroid dysfunction (chronic use)"},{"rate":"1-3","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1083993","moleculeType":"Small molecule","molecularWeight":"681.78"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amiodarone works primarily through potassium channel blockade, which delays repolarization and extends the action potential duration. It also has properties of all four Vaughan-Williams antiarrhythmic classes, including sodium channel blockade, beta-adrenergic antagonism, and calcium channel inhibition. This multi-channel activity makes it effective for suppressing various cardiac arrhythmias.","oneSentence":"Intravenous amiodarone is a Class III antiarrhythmic agent that blocks potassium channels and prolongs the action potential duration and refractory period to restore normal heart rhythm.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:52.981Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation with rapid ventricular response"},{"name":"Ventricular tachycardia"},{"name":"Ventricular fibrillation"},{"name":"Supraventricular tachycardia"}]},"trialDetails":[{"nctId":"NCT05524077","phase":"NA","title":"Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Western Sydney Local Health District","startDate":"2020-07-08","conditions":"Heart Disease Structural Disorder, Ventricular Tachycardia, Cardiomyopathy, Dilated","enrollment":162},{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":"Acute Aluminum Phosphide Poisoned Cases","enrollment":74},{"nctId":"NCT06553391","phase":"","title":"Heart Rhythm Changes in Patients With Atrial Fibrillation After Cardiopulmonary Bypass: a Retrospective Analysis","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2024-08-01","conditions":"Atrial Fibrillation","enrollment":106},{"nctId":"NCT06930599","phase":"NA","title":"Circumferential Pulmonary Vein Isolation Plus Transition Zone Modification in Atrial Fibrillation Patients Without Low-Voltage Areas","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-04-09","conditions":"Atrial Fibrillation (AF)","enrollment":162},{"nctId":"NCT05445297","phase":"PHASE4","title":"Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter","status":"COMPLETED","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2022-01-26","conditions":"Atrial Fibrillation Paroxysmal","enrollment":60},{"nctId":"NCT06817447","phase":"NA","title":"Pulmonary Vein Isolation in Typical Atrial Flutter and Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-03-01","conditions":"Atrial Flutter Typical, Heart Failure","enrollment":168},{"nctId":"NCT05391893","phase":"PHASE4","title":"Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation","status":"COMPLETED","sponsor":"Corewell Health South","startDate":"2020-06-19","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":444},{"nctId":"NCT06742866","phase":"NA","title":"Efficacy and Safety of Intravenous + Oral Vs. Oral Amiodarone in Preventing Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-12-16","conditions":"Atrial Fibrillation (AF)","enrollment":418},{"nctId":"NCT01422148","phase":"PHASE2","title":"Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Baystate Medical Center","startDate":"2025-07","conditions":"Atrial Fibrillation","enrollment":60},{"nctId":"NCT05169866","phase":"PHASE3","title":"Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2022-05-29","conditions":"New Onset Atrial Fibrillation, Complications; Cardiac, Postoperative","enrollment":274},{"nctId":"NCT04748991","phase":"PHASE3","title":"Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2024-09","conditions":"Atrial Fibrillation, Post-cardiac Surgery","enrollment":50},{"nctId":"NCT05287191","phase":"PHASE3","title":"MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-01-05","conditions":"Atrial Fibrillation New Onset","enrollment":200},{"nctId":"NCT05058053","phase":"NA","title":"THE EFFECT OF COLD APPLICATION ON THE DEVELOPMENT OF PHLEBITIS IN PATIENTS RECEIVING INTRAVENOUS AMIODARONE TREATMENT.","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2020-03-01","conditions":"Phlebitis","enrollment":100},{"nctId":"NCT05004077","phase":"PHASE4","title":"Repeated Amiodarone Dosing In Cardiac surgicaL Procedures","status":"TERMINATED","sponsor":"Kevin W Hatton, MD, PhD","startDate":"2021-11-02","conditions":"Atrial Fibrillation","enrollment":3},{"nctId":"NCT05950971","phase":"NA","title":"Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2021-07-01","conditions":"Atrial Fibrillation New Onset, Atrial Fibrillation Paroxysmal","enrollment":1},{"nctId":"NCT04392921","phase":"NA","title":"Prophylaxis for Patients at Risk to Eliminate Post-operative Atrial Fibrillation","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2022-03-07","conditions":"Atrial Fibrillation","enrollment":80},{"nctId":"NCT04234906","phase":"PHASE4","title":"Prevention of Post-Operative Cardiac Arrhythmias","status":"UNKNOWN","sponsor":"Jeffrey Moak","startDate":"2023-01","conditions":"Cardiac; Dysrhythmia, Postoperative, Congenital Heart Surgery","enrollment":870},{"nctId":"NCT04092621","phase":"PHASE4","title":"Rapid Atrial Fibrillation Treatment Strategy","status":"UNKNOWN","sponsor":"Our Lady of the Lake Hospital","startDate":"2019-09-16","conditions":"New Onset Atrial Fibrillation, Sepsis, Respiratory Failure","enrollment":40},{"nctId":"NCT02668432","phase":"PHASE4","title":"Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock","status":"TERMINATED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-05","conditions":"New Onset Atrial Fibrillation, Severe Sepsis, Septic Shock","enrollment":9},{"nctId":"NCT03855826","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.","status":"UNKNOWN","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2019-01-15","conditions":"Ventricular Tachycardia, Ventricular Fibrillation","enrollment":756},{"nctId":"NCT03432663","phase":"PHASE4","title":"Time-dependent Amiodarone Treatment in Atrial Fibrillation","status":"COMPLETED","sponsor":"Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud","startDate":"2008-08-01","conditions":"Atrial Fibrillation","enrollment":60},{"nctId":"NCT02025465","phase":"PHASE4","title":"Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control","status":"UNKNOWN","sponsor":"CAMC Health System","startDate":"2013-12","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":150},{"nctId":"NCT01401647","phase":"PHASE3","title":"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-05","conditions":"Cardiac Arrest","enrollment":3024},{"nctId":"NCT00383799","phase":"PHASE4","title":"Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia","status":"TERMINATED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2005-09","conditions":"Ventricular Tachycardia, Wide QRS Tachycardia","enrollment":302},{"nctId":"NCT02114528","phase":"PHASE4","title":"Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2014-10","conditions":"Ventricular Tachycardia, Ventricular Arrhythmia","enrollment":40},{"nctId":"NCT02307591","phase":"PHASE2, PHASE3","title":"Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)","status":"WITHDRAWN","sponsor":"Emergency NGO Onlus","startDate":"2014-12","conditions":"Ebola Virus Disease","enrollment":""},{"nctId":"NCT00121524","phase":"PHASE2","title":"Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome","status":"COMPLETED","sponsor":"Petter Andreas Steen","startDate":"2003-01","conditions":"Cardiac Arrest","enrollment":904},{"nctId":"NCT00127712","phase":"PHASE4","title":"Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery","status":"COMPLETED","sponsor":"Indiana University","startDate":"2004-09","conditions":"Atrial Fibrillation","enrollment":130},{"nctId":"NCT00420017","phase":"PHASE4","title":"Prevention of Atrial Fibrillation Following Esophagectomy","status":"COMPLETED","sponsor":"Indiana University","startDate":"2005-09","conditions":"Atrial Fibrillation, Esophagectomy","enrollment":80},{"nctId":"NCT01627106","phase":"PHASE4","title":"A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)","status":"WITHDRAWN","sponsor":"Advanz Pharma","startDate":"2012-09","conditions":"Atrial Fibrillation","enrollment":""},{"nctId":"NCT01817439","phase":"PHASE3","title":"Safety and Efficacy of Oral Versus Intravenous Amiodarone in the Treatment of AF","status":"UNKNOWN","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2013-05","conditions":"Atrial Fibrillation","enrollment":104},{"nctId":"NCT00816192","phase":"NA","title":"Comparison of Externally Versus Internally Cooled Tip Catheter Ablation in Paroxysmal Atrial Fibrillation","status":"TERMINATED","sponsor":"University Hospital, Bordeaux","startDate":"2008-12","conditions":"Atrial Fibrillation","enrollment":86},{"nctId":"NCT00784316","phase":"PHASE4","title":"Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2007-08","conditions":"Atrial Fibrillation, Cardiac Surgery","enrollment":316},{"nctId":"NCT00724581","phase":"PHASE4","title":"Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer","status":"UNKNOWN","sponsor":"Aarhus University Hospital","startDate":"2008-08","conditions":"Atrial Fibrillation","enrollment":275}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":575,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["72 hour amiodarone"],"phase":"marketed","status":"active","brandName":"Intravenous amiodarone(2)","genericName":"Intravenous amiodarone(2)","companyName":"Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud","companyId":"instituto-de-cardiolog-a-y-medicina-vascular-hospital-zambrano-hellion-tec-salud","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravenous amiodarone is a Class III antiarrhythmic agent that blocks potassium channels and prolongs the action potential duration and refractory period to restore normal heart rhythm. Used for Atrial fibrillation with rapid ventricular response, Ventricular tachycardia, Ventricular fibrillation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}